Skip to main content

Table 3 Cardiac MRI Functional and Fibrosis data

From: Diffuse left ventricular interstitial fibrosis is associated with sub-clinical myocardial dysfunction in Alström Syndrome: an observational study

 

Controls

ALMS

 

ALMS

 
   

ECV < ULN

ECV > ULN

ECV > ULN

    

NO LGE

LGE

Number n

26

26

12

5

9

Mean global ECV

0.25 ± 0.01

0.30 ± 0.05*

0.25 ± 0.02

0.31 ± 0.03a

0.34 ± 0.05b

Global pre contrast T1 (ms)

970 ± 11

949 ± 35

934 ± 34

952 ± 33

972 ± 35

Global post contrast T1 (ms)

522 ± 58

465 ± 61*

472 ± 54

440 ± 47

437 ± 43

Diffuse LGE n

0

9

0

0

9

LVEDV (ml)

133 ± 29

105 ± 23**

107 ± 31

100 ± 13

108 ± 25

LVEDV index (ml/m2)

69 ± 12

57 ± 11**

57 ± 13

56 ± 11

58 ± 13

LVESV(ml)

43 ± 13

38 ± 15

37 ± 15

32 ± 8

43 ± 19

LVESV index (ml/m2)

22 ± 6

20 ± 8

20 ± 7

18 ± 5

23 ± 10

LVEF (%)

68 ± 5

66 ± 8

67 ± 7

69 ± 5

62 ± 11

LV mass (g)

115 ± 31

104 ± 27

106 ± 27

87 ± 13

112 ± 34

LV mass index (g/m2)

60 ± 14

56 ± 12

56 ± 10

48 ± 8

60 ± 16

LV mass/ Height2.7 (g/m2.7)

25 ± 6

29 ± 7*

28 ± 6

24 ± 6

32 ± 9

LA volume (ml/m2)

33 ± 8

35 ± 15

29 ± 8

40 ± 14

39 ± 15

MAPSE (mm)

17 ± 2

12 ± 2*

13 ± 2

13 ± 3

11 ± 3

Global long SS (%)

14.7 ± 2.3

11.2 ± 2.6**

12.9 ± 1.0

10.9 ± 2.0a

9.6 ± 1.9b

Global long SSR (s−1)

0.83 ± 0.15

0.57 ± 0.11**

0.63 ± 0.16

0.53 ± 0.11a

0.52. ± 0.15b

Global long ESR (s−1)

0.62 ± 0.15

0.49 ± 0.18*

0.54 ± 0.15

0.44 ± 0.19

0.41 ± 0.19

  1. EDV end-diastolic volume, ESV end-systolic volume, EF ejection fraction, LA left atrium, LGE late gadolinium enhancement, long; longitudinal, LV left ventricle, MAPSE mitral annular plane systolic excursion, RV right ventricle, TAPSE tricuspid annular plane systolic excursion, SS systolic strain, SR systolic strain rate, ESR early diastolic strain rate, ULN ECV above the upper limit (0.279) observed in matched control
  2. a p < 0.05, Bonferroni post-hoc tests for differences ECV above upper limit of normal controls vs. increased ECV no LGE
  3. b p <0.05, Bonferroni post-hoc tests for differences ECV above upper limit of normal controls vs. increased ECV with LGE
  4. ANOVA * p <0.05, ** <0.01, ALMS vs. controls